vs
LINKBANCORP, Inc.（LNKB）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
LINKBANCORP, Inc.的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.3倍（$46.0M vs $35.5M），LINKBANCORP, Inc.净利率更高（6.4% vs -304.2%，领先310.6%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 7.3%），LINKBANCORP, Inc.自由现金流更多（$23.8M vs $-47.3M），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 6.6%）
LINKBANCORP是一家总部位于美国的银行控股公司，主要为宾夕法尼亚州地区的个人消费者、小微企业和中型企业提供零售与商业银行服务，涵盖存款账户、贷款产品、财富管理解决方案及数字银行服务等核心业务。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
LNKB vs RXRX — 直观对比
营收规模更大
LNKB
是对方的1.3倍
$35.5M
营收增速更快
RXRX
高出674.5%
7.3%
净利率更高
LNKB
高出310.6%
-304.2%
自由现金流更多
LNKB
多$71.1M
$-47.3M
两年增速更快
RXRX
近两年复合增速
6.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $46.0M | $35.5M |
| 净利润 | $2.9M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 8.5% | -304.8% |
| 净利率 | 6.4% | -304.2% |
| 营收同比 | 7.3% | 681.7% |
| 净利润同比 | -61.2% | 39.6% |
| 每股收益（稀释后） | $0.08 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LNKBRXRX
| Q4 25 | $46.0M | $35.5M | ||
| Q3 25 | $44.8M | $5.2M | ||
| Q2 25 | $42.3M | $19.2M | ||
| Q1 25 | $53.4M | $14.7M | ||
| Q4 24 | $42.9M | $4.5M | ||
| Q3 24 | $42.9M | $26.1M | ||
| Q2 24 | $41.3M | $14.4M | ||
| Q1 24 | $40.5M | $13.8M |
净利润LNKBRXRX
| Q4 25 | $2.9M | $-108.1M | ||
| Q3 25 | $7.8M | $-162.3M | ||
| Q2 25 | $7.4M | $-171.9M | ||
| Q1 25 | $15.3M | $-202.5M | ||
| Q4 24 | $7.6M | $-178.9M | ||
| Q3 24 | $7.1M | $-95.8M | ||
| Q2 24 | $5.8M | $-97.5M | ||
| Q1 24 | $5.7M | $-91.4M |
毛利率LNKBRXRX
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% | ||
| Q1 24 | — | 19.1% |
营业利润率LNKBRXRX
| Q4 25 | 8.5% | -304.8% | ||
| Q3 25 | 22.3% | -3327.6% | ||
| Q2 25 | 22.4% | -916.8% | ||
| Q1 25 | 36.0% | -1297.9% | ||
| Q4 24 | 22.6% | -4042.4% | ||
| Q3 24 | 21.3% | -377.1% | ||
| Q2 24 | 18.0% | -697.4% | ||
| Q1 24 | 18.1% | -698.4% |
净利率LNKBRXRX
| Q4 25 | 6.4% | -304.2% | ||
| Q3 25 | 17.5% | -3135.3% | ||
| Q2 25 | 17.5% | -894.2% | ||
| Q1 25 | 28.7% | -1373.3% | ||
| Q4 24 | 17.7% | -3935.5% | ||
| Q3 24 | 16.5% | -367.5% | ||
| Q2 24 | 14.1% | -676.6% | ||
| Q1 24 | 14.1% | -662.4% |
每股收益（稀释后）LNKBRXRX
| Q4 25 | $0.08 | $-0.17 | ||
| Q3 25 | $0.21 | $-0.36 | ||
| Q2 25 | $0.20 | $-0.41 | ||
| Q1 25 | $0.41 | $-0.50 | ||
| Q4 24 | $0.21 | $-0.56 | ||
| Q3 24 | $0.19 | $-0.34 | ||
| Q2 24 | $0.16 | $-0.40 | ||
| Q1 24 | $0.15 | $-0.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $52.3M | $743.3M |
| 总债务越低越好 | $177.3M | $9.6M |
| 股东权益账面价值 | $306.4M | $1.1B |
| 总资产 | $3.1B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.58× | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资LNKBRXRX
| Q4 25 | $52.3M | $743.3M | ||
| Q3 25 | $194.2M | $659.8M | ||
| Q2 25 | $155.1M | $525.1M | ||
| Q1 25 | $220.2M | $500.5M | ||
| Q4 24 | $166.1M | $594.4M | ||
| Q3 24 | $191.2M | $427.6M | ||
| Q2 24 | $181.7M | $474.3M | ||
| Q1 24 | $172.3M | $296.3M |
总债务LNKBRXRX
| Q4 25 | $177.3M | $9.6M | ||
| Q3 25 | $102.3M | $11.9M | ||
| Q2 25 | $102.3M | $14.2M | ||
| Q1 25 | $102.7M | $16.4M | ||
| Q4 24 | $112.5M | $19.0M | ||
| Q3 24 | $102.4M | $20.5M | ||
| Q2 24 | $102.3M | $22.9M | ||
| Q1 24 | $102.2M | — |
股东权益LNKBRXRX
| Q4 25 | $306.4M | $1.1B | ||
| Q3 25 | $305.5M | $1.0B | ||
| Q2 25 | $298.0M | $919.1M | ||
| Q1 25 | $294.1M | $933.9M | ||
| Q4 24 | $280.2M | $1.0B | ||
| Q3 24 | $277.4M | $524.6M | ||
| Q2 24 | $271.4M | $584.4M | ||
| Q1 24 | $268.2M | $401.2M |
总资产LNKBRXRX
| Q4 25 | $3.1B | $1.5B | ||
| Q3 25 | $3.1B | $1.4B | ||
| Q2 25 | $2.9B | $1.3B | ||
| Q1 25 | $2.9B | $1.3B | ||
| Q4 24 | $2.9B | $1.4B | ||
| Q3 24 | $2.9B | $726.5M | ||
| Q2 24 | $2.9B | $775.9M | ||
| Q1 24 | $2.8B | $557.8M |
负债/权益比LNKBRXRX
| Q4 25 | 0.58× | 0.01× | ||
| Q3 25 | 0.33× | 0.01× | ||
| Q2 25 | 0.34× | 0.02× | ||
| Q1 25 | 0.35× | 0.02× | ||
| Q4 24 | 0.40× | 0.02× | ||
| Q3 24 | 0.37× | 0.04× | ||
| Q2 24 | 0.38× | 0.04× | ||
| Q1 24 | 0.38× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $25.3M | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | $23.8M | $-47.3M |
| 自由现金流率自由现金流/营收 | 51.7% | -133.1% |
| 资本支出强度资本支出/营收 | 3.2% | 3.5% |
| 现金转化率经营现金流/净利润 | 8.59× | — |
| 过去12个月自由现金流最近4个季度 | $55.3M | $-378.3M |
8季度趋势，按日历期对齐
经营现金流LNKBRXRX
| Q4 25 | $25.3M | $-46.1M | ||
| Q3 25 | $23.6M | $-117.4M | ||
| Q2 25 | $6.3M | $-76.4M | ||
| Q1 25 | $2.6M | $-132.0M | ||
| Q4 24 | $25.4M | $-115.4M | ||
| Q3 24 | $14.0M | $-59.2M | ||
| Q2 24 | $6.4M | $-82.2M | ||
| Q1 24 | $-771.0K | $-102.3M |
自由现金流LNKBRXRX
| Q4 25 | $23.8M | $-47.3M | ||
| Q3 25 | $23.2M | $-117.6M | ||
| Q2 25 | $6.1M | $-79.6M | ||
| Q1 25 | $2.2M | $-133.8M | ||
| Q4 24 | $22.6M | $-116.7M | ||
| Q3 24 | $13.1M | $-63.8M | ||
| Q2 24 | $6.3M | $-83.4M | ||
| Q1 24 | $-1.2M | $-109.0M |
自由现金流率LNKBRXRX
| Q4 25 | 51.7% | -133.1% | ||
| Q3 25 | 51.8% | -2272.5% | ||
| Q2 25 | 14.5% | -413.9% | ||
| Q1 25 | 4.2% | -907.4% | ||
| Q4 24 | 52.6% | -2567.7% | ||
| Q3 24 | 30.5% | -244.6% | ||
| Q2 24 | 15.3% | -578.5% | ||
| Q1 24 | -3.0% | -789.9% |
资本支出强度LNKBRXRX
| Q4 25 | 3.2% | 3.5% | ||
| Q3 25 | 0.8% | 4.7% | ||
| Q2 25 | 0.4% | 16.4% | ||
| Q1 25 | 0.7% | 12.4% | ||
| Q4 24 | 6.7% | 28.6% | ||
| Q3 24 | 2.1% | 17.5% | ||
| Q2 24 | 0.1% | 8.2% | ||
| Q1 24 | 1.1% | 48.2% |
现金转化率LNKBRXRX
| Q4 25 | 8.59× | — | ||
| Q3 25 | 3.01× | — | ||
| Q2 25 | 0.85× | — | ||
| Q1 25 | 0.17× | — | ||
| Q4 24 | 3.35× | — | ||
| Q3 24 | 1.97× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | -0.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
